Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

29 June 2020

Pharma giants to unveil major $1 billion venture to push novel antibiotics

This article by Ed Silverman for STAT looks at upcoming efforts by a number of large drug companies to acquire or invest in small antibotic makers and their medicines in the midst of growing concerns about antibiotic resistance.

Direct links

Read the full article

In the article, the author sets the stage for an upcoming move, due to be announced on July 9th, for a variety of large pharmaceutical companies to take on the "antibiotic innovation challenge." The author notes that this $1 billion initiative will be supported by the World Health Organization and the European Investment Bank.

The article refers to the Access to Medicine Foundation's 2020 Antimicrobial Resistance Benchmark findings that antibiotic production has increased only slightly in the past two years, with a few small and medium-sized companies leading the production of these drugs. 


Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved